key: cord-0783187-68kqtgoy authors: Natarajan, A.; Su, H.-W.; Heneghan, C. title: Occurrence of relative bradycardia and relative tachycardia in individuals diagnosed with COVID-19 date: 2022-02-03 journal: nan DOI: 10.1101/2022.02.02.22270342 sha: 8744aca1d1c81ec37fd454e640ff8a76039c448a doc_id: 783187 cord_uid: 68kqtgoy Background: The COVID-19 disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) has become one of the worst global pandemics of the century causing tremendous human and economic suffering worldwide. While considered a respiratory disease, COVID-19 is known to cause cardiac complications. Wearable devices are well equipped to measure heart rate continuously and their popularity makes them valuable devices in the field of digital health. In this article, we use Fitbit devices to examine resting heart rate from individuals diagnosed with COVID-19. Methods: The Fitbit COVID-19 survey was conducted from May 2020 - June 2021. We collected resting heart rate data from 7,200 individuals (6,606 symptomatic, 594 asymptomatic) diagnosed with COVID- 19 between March 2020 - December 2020, as well as from 463 individuals diagnosed with influenza between January 2020 - December 2020. Data from healthy individuals served as a control, in order to model the seasonal variation. We also computed heart rate variability and respiratory rate data for symptomatic COVID-19. Findings: Resting Heart Rate is elevated during COVID-19 symptom onset, with average peak increases relative to the baseline of 1.8%+/-0.1% (3.4%+/-0.2%) for females (males), where the quoted numbers are mean and standard error of the mean. After the initial peak, the resting heart rate decreased and reached a minimum on average ~ 13 days after symptom onset. The minimum value relative to the baseline is more negative for females (-1.75% +/- 0.1%) compared to males (0.08% +/- 0.2%). The resting heart rate then increased, reaching a second peak on average ~ 28 days from symptom onset, before falling back to the baseline ~ 112 days from symptom onset. All estimates vary with disease severity. Interpretation: The resting heart rate is modified for several months following a COVID-19 diagnosis. Interestingly, this effect is seen with seasonal influenza also, although the bradycardia minimum and the second tachycardia peak are often more pronounced in the case of symptomatic COVID-19. By computing resting heart rate daily, wearable devices can contribute to monitoring wellness during recovery from COVID-19, and seasonal influenza. Funding: A.N., H.-W.S., and C.H. are supported by Fitbit Research, Google LLC. Cardiac complications are known to be associated with the COVID-19 disease caused by 26 the novel Severe Acute Respiratory Syndrome -Coronavirus 2 (SARS-CoV-2) 1-8 . Cardiac 27 a This feature is not intended to diagnose or treat any medical condition and should not be relied on for any medical purposes. It is provided to Fitbit users to help manage well-being. 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. ; https://doi.org/10.1101/2022.02.02.22270342 doi: medRxiv preprint injury, heart failure, and arrhythmias have been recorded in patients diagnosed with COVID-28 19 1, 5, 9, 10 . 29 An unusual feature that is sometimes seen in patients diagnosed with COVID-19 is the 30 appearance of bradycardia, i.e. slow heart rate, or heart rate not increasing as expected 31 with body temperature 11-14 . Amaratunga et al. 15 found bradycardia in a study of 4 patients 32 with confirmed COVID-19, with minimum pulse rates in the range 42−49 beats per minute. 33 Amir et al. 16 Commercially available wearable devices have been shown to be useful in early detection 46 of COVID-19 and for monitoring symptoms 24-29 . Radin et al. 30 studied resting heart rate 47 (henceforth RHR) data from Fitbit devices to investigate long term changes following symp-48 tom onset. RHR is typically elevated around symptom onset. We use the term "relative" 49 to indicate that the RHR is elevated/decreased relative to the baseline value for that indi-50 vidual, although the RHR is not necessarily above/below the clinical threshold guideline 31 . They also found the RHR exhibits a dip which we refer to as transient relative bradycardia 52 provided the RHR is below the baseline value. The RHR dip was followed by a second ele-53 vated RHR peak. They found that the RHR was elevated for up to 79 days from symptom 54 onset. 55 In this article, we obtain results consistent with the findings of Radin et al., and ex-56 pand upon existing work in a number of ways. We study a much larger sample size than 57 previously considered. We investigate how the resting heart range changes, for male and 58 female individuals, and for individuals with severe, mild or asymptomatic presentations of 59 4 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2022. ; https://doi.org/10.1101/2022.02.02.22270342 doi: medRxiv preprint COVID-19. We also consider individuals diagnosed with the seasonal influenza (henceforth 60 "flu"). We tabulate the expected amplitudes of the maxima/minima, as well as the time 61 taken to reach these maxima/minima, and the estimated widths of the peaks/troughs. We 62 examine how these parameters vary with age, sex, and disease severity. We also study heart 63 rate variability and respiratory rate and how these metrics vary with time. A. Survey Data The Fitbit COVID-19 survey was conducted from May 21, 2020 to June 10, 2021, and 67 collected data from participants residing in the USA or Canada. Participants provided in-68 formation on whether they were diagnosed with COVID-19 or flu, as well as the test date, 69 symptoms, and the start date of symptoms. Participants could optionally provide infor-70 mation about their age, sex, body mass index, and information on underlying conditions. Individuals diagnosed with COVID-19 also indicated the severity of the disease which could 72 be (i) severe, indicating that they required hospitalization, (ii) mild, indicating that they 73 recovered at home, or (iii) asymptomatic. The survey and associated marketing and recruit-74 ment materials were approved by an Institutional Review Board (Advarra). The participants 75 provided electronic informed consent for their data to be used for research. In this study, 76 we consider data from Fitbit users who reported testing positive for COVID-19 in the date 77 range March 1 -Dec 31, 2020, as well as users who reported testing positive for flu in the 78 date range Jan 1 -Dec 31, 2020. There were 11,918 participants who tested positive for 79 COVID-19 (mean age = 40.8 yr, std. dev. = 12.4 yr, 79.0% female) in our dataset, and 80 865 participants who tested positive for flu (mean age = 41.7 yr, std. dev. = 13.3 yr, 81 78.2% female). We randomly select 1,000 users who did not report a positive test for either 82 COVID-19 or flu as a control group (mean age = 45.3 yr, std. dev. = 13.9 yr, 71.6% fe-83 male). Table I shows the prevalence of symptoms (self reported) for COVID-19 and flu, for 84 male and female participants (for COVID-19, we also separate by disease severity). Some 85 symptoms such as fatigue, headache and body ache are common for both COVID-19 and 86 flu. By contrast, a decrease in taste and/or smell is more likely in the case of COVID-19 87 (72.6% female, 59.8% male) compared to flu (21.2% female, 11.6% male). Fever is more 88 5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) We measure the RHR from participants in our study, collected using Fitbit devices. The "resting heart rate" as defined by Fitbit is the value closest to the heart rate measured when 95 lying down just before waking up in the morning 32 . RHR is computed using heart rate data during sleep when sleep data is available, and 97 a proprietary algorithm is utilized to predict the RHR from the time series heart rate data 98 during sleep. If sleep data is unavailable, RHR is computed using wake time heart rate data, 99 at times when no activity is detected. The RHR is also processed with a Kalman filter which 100 serves to smooth the waveform. Note that the RHR is not the minimum value of heart rate. We compute the fractional change in RHR ξ from days D −14 to D +180 as: where d is a variable indicating day index. 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. lation's average RHR by 2 beats per minute (bpm). In the Northern hemisphere, the RHR 115 peaks in the first week of January and reaches its minimum at the end of July. Since all participants in our study reside in the USA or Canada, we assume that they are 117 subject to the same seasonal trends. We use the control group to estimate how RHR varies 118 with the time of year, by applying Eq. 1 to obtain ξ control as follows: 119 1. Randomly sample a date from the COVID-19 or flu distribution and set to D 0 (date 120 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. of symptom onset). 2. Compute ξ control (d) using Eq. 1 from the control group for dates d relative to D 0 . We may then subtract out the seasonality to find the effect of illness on RHR: where α may be flu or COVID-19. Note that ξ control must be computed twice: once for the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. Table II. from the onset of symptoms. If A b < 0, we refer to the trough as transient relative 3. Following the minimum, ∆ξ increases again, reaching a second peak A t2 at a time T t2 163 days from symptom onset. This is the second transient relative tachycardia. 164 4. Past T t2 , ∆ξ decreases and eventually falls to zero, indicating that the RHR variation 165 11 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. ; https://doi.org/10.1101/2022.02.02.22270342 doi: medRxiv preprint is no longer due to illness. 166 The parameters A t1 , A b , A t2 , T t1 , T b , T t2 , W t1 , W b , and W t2 are marked in subplot (d), and 167 described in Table II . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. ∆ξ. The magenta curve is plotted for severe cases (i.e cases that required hospitalization). The brown curve shows mild cases, while the green curve is plotted for asymptomatic cases. The blue curve shows ∆ξ for flu. The amplitudes of the two relative tachycardia peals A t1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. ; https://doi.org/10.1101/2022.02.02.22270342 doi: medRxiv preprint 14 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. • Presumed "relative bradycardia" window from D +7 to D +21 . • Presumed "relative tachycardia" window from D +22 to D +36 . The healthy and control windows are expected to contain data when participants are 208 healthy. The RHR is averaged over each window, and we only consider participants who 209 have 15 days of data in each window. Let ∆RHR w be the difference between the RHR 210 averaged over window w and the RHR averaged over the control window: (3) We compute the fraction of participants who have ∆RHR ≤ x bpm, computed from the plotted in green which is an estimate of how likely it is that such a low ∆RHR may occur 220 due to random chance. Fig. 5(b) shows a similar comparison, but for ∆RHR ≥ x, and 221 considering the tachycardia window. Interestingly, there is a correlation between the peak value of ∆RHR measured during relative bradycardia window (D +7 to D +21 ). Fig. 6 shows this correlation. The horizontal 226 axis is ∆RHR during symptom onset, while the vertical axis shows ∆RHR during either the 227 second tachycardia phase (red) or the bradycardia phase (blue). We see that ∆RHR tachy 228 measured in the second relative tachycardia phase is positively correlated with ∆RHR symptom , 229 the peak value observed at symptom onset. Similarly, ∆RHR brady , the minimum value 230 observed during the relative bradycardia phase is positively correlated with ∆RHR symptom . This means that a low ∆RHR at symptom onset is indicative of a decreased RHR in the 232 relative bradycardia phase. An approximate estimate of ∆RHR tachy and ∆RHR brady may 233 18 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. Let us now briefly consider 2 more health metrics: the heart rate variability quantified 236 by the root mean square of the successive differences (RMSSD) and the respiratory rate. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. ; https://doi.org/10.1101/2022.02.02.22270342 doi: medRxiv preprint variation of the RHR (Fig. 3) and the time variation of the RMSSD (Fig. 7) . 273 The parameters that describe the time evolution of the RHR depend on sex, age, and 274 disease severity and are tabulated in Tables III, IV Pearson r for the correlation between T b and age was found to be r = 0.98 for females and 279 r = 0.77 for males). The width of the first relative tachycardia peak W t1 is also correlated 280 with age (r = 0.83 for females, and r = 0.94 for males). Interestingly, mild cases of COVID-19 are more likely to present with relative bradycardia. It is also more likely to present in females compared to males. A possible explanation for 292 this may be obtained from Fig. 6 , and Table I . Fig. 6 shows that the peak RHR during 293 symptom onset is positively correlated with the magnitude of the dip, i.e. a smaller peak 294 RHR during symptom onset is associated with a larger (and possibly negative) dip. It is well 295 known the heart rate is strongly linked to temperature, increasing by 8.5 bpm per 1 degree 296 C increase in temperature, as found in one study 43 . As seen from Table I, males are more 297 21 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2022. ; https://doi.org/10.1101/2022.02.02.22270342 doi: medRxiv preprint likely to present with a fever compared to females. Similarly, fever is more common in severe 298 cases compared to mild cases. Thus, females as well as mild cases presenting with a small 299 RHR increase (or no increase) are more likely to experience a bradycardia dip compared to 300 males, or severe cases. Similarly, Fig. 6 shows that the peak RHR during symptom onset is 301 positively correlated with the height of the second tachycardia peak. As a result, the second 302 tachycardia peak is higher in males, and for severe cases. The heart rate variability shows 303 a similar time evolution as the resting heart rate, except with opposite phase. Fig. 7 shows 304 the time evolution of the RMSSD (subplot (a)) and the respiratory rate (subplot (b)) with 305 time. Unlike the RMSSD, the respiratory rate decreases monotonously past the initial peak. There are several limitations to the current work. A major concern is that we do not know 309 whether the individuals who were diagnosed with COVID-19 and flu received medications 310 to treat their illness, and what effects those medications may have had on their heart rate. The symptoms, severity, as well as symptom start date were all obtained from a survey, 312 and could not be independently verified. We have also assumed that the participants were CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2022. Our consent form and the protocol allow us to make the raw data available to two CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2022. ; https://doi.org/10.1101/2022.02.02.22270342 doi: medRxiv preprint Recognizing COVID-19-related myocarditis: The possible pathophysiology 350 and proposed guideline for diagnosis and management Worldwide Survey of COVID-19-Associated Arrhyth-363 mias Cardiac and arrhythmic 365 complications in patients with COVID-19 Cardiovascular complications in COVID-367 19 COVID-19 myopericarditis: It should be 369 kept in mind in today's conditions Cardiac 372 complications in patients hospitalised with COVID-19 Nourmo-377 hammadi, and R. Mosaed Relative bradycardia in 381 patients with COVID-19 COVID-19 induced bradyarrhythmia and relative bradycardia: An overview Prevalence 386 and clinical significance of relative bradycardia at hospital admission in patients with coron-387 avirus disease 2019 (COVID-19) Bradycardia in Patients With 389 COVID-19: A Calm Before the Storm? Bradycardia in Covid-19 Hospitalized Patients: A Case Series Marked self-limiting sinus 395 bradycardia in COVID-19 patients not requiring therapy in the intensive care unit -case series 396 report Systemic Inflammation-Related Bradycardia in COVID-19 Cardiovascular sequalae in uncomplicated 403 COVID-19 survivors Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease COVID-19 and cardiac arrhythmias Ar-413 rhythmias and COVID-19: A Review Novel 415 coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series Analyzing changes in respiratory rate to predict the risk of COVID-19 infection Pre-symptomatic 423 detection of COVID-19 from smartwatch data Wearable sensor data and self-reported symptoms for COVID-19 426 detection Assessment of physiological signs associated with 428 COVID-19 measured using wearable devices Measurement 430 of respiratory rate using wearable devices and applications to COVID-19 detection Home Monitoring of Cardiac Devices in the Era of 433 COVID-19 Resting pulse rate 438 reference data for children, adolescents, and adults: United States the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted Investigation of an estimate of daily rest-441 ing heart rate using a consumer wearable device Inter-and intraindividual 444 variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time 445 of year: Retrospective, longitudinal cohort study of 92,457 adults The jackknife-a review Nonparametric estimates of standard error: The jackknife, the bootstrap and other 449 methods Heart rate variability 451 with photoplethysmography in 8 million individuals: a cross-sectional study Seasonal Influenza 454 Infections and Cardiovascular Disease Mortality Pathogen-456 induced heart rate changes associated with cholinergic nervous system activation Clinical analysis of sinus bradycardia 459 in patients with severe COVID-19 pneumonia Cardiac Adverse Events With 461 Remdesivir in COVID-19 Infection Severe sinus bradycardia 463 associated with Remdesivir in a child with severe SARS-CoV-2 infection Remdesivir-induced symptomatic brady-466 cardia in the treatment of COVID-19 disease the author/funder, who has granted medRxiv a license to display the preprint in perpetuity